[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gender-identity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gender-identity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,67,90,124],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100499762","state-of-hormones-impact-nociceptive-expression-100499762",false,"NCT05787470","State of Hormones Impact Nociceptive Expression","SHINE","Inclusion Criteria:\n\n* self-identification as one of the above gender identities\n* understanding of verbal and written English.\n* participants that have been on\u002Foff hormone treatment for at least 6 months\n\nExclusion Criteria:\n\n* pain in at least 3\u002F7 days\u002Fweek for the past 3 months\n* HIV positive diagnosis\n* cardiovascular or pulmonary disease\n* regular use of opioid pain medications\n* uncontrolled hypertension (i.e. SBP\u002FDBP of \\> 150\u002F95)\n* current illness accompanied by fever (body temperature \\>38 °C)\n* prostatectomy, hysterectomy or oophorectomy\n* hospitalization due to psychiatric illness within the last 6 months.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW \\> CM), but found that the TW were phenotypically similar to CW in all measures. However, the investigators did not assess hormone level, nor did the investigators recruit TM participants. Here, with the assistance of two local community group stakeholders the investigators will recruit the following groups: CM, CW, TM+T (currently taking exogenous testosterone), TW+E (exogenous estradiol), TM, and TW (n=20\u002Fgroup). The investigators will use quantitative sensory testing to assess sensitivity to cold, pressure, and heat via standardized protocols. Blood samples will be taken for assessment of stress and reproductive hormone levels, immune cell populations and stimulated cytokine release. Finally, questionnaires will measure pain state, quality of life (QOL), voice QOL, body image, appearance, self-reported health, masculinity\u002Ffemininity, community connectedness, gender role, sleep, depression, social support, adverse childhood experiences and stigma.",[26,27],"Pain","Gender Identity","RECRUITING","2026-07-01",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2023-03-01",{"date":36,"type":22},"2027-07-31",{"name":38,"class":39},"University of Alabama at Birmingham","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100529732","transhealthguide-transforming-health-for-gender-diverse-young-adults-100529732","NCT06177600","TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults","TransHealthGUIDE: Transforming Health for Gender-Diverse Young Adults Using Interventions to Drive Equity","Inclusion Criteria:\n\n* Gender diverse individuals aged 18-29 years residing in California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York\n* Caregivers of gender diverse individuals aged 18-29 years residing in California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York\n\nExclusion Criteria:\n\n* Inability to speak, read, and write English\n* Lack of device with Internet access\n* Current residence in location other than California, Oregon, Illinois, Maryland, District of Columbia, Vermont, Connecticut, Massachusetts, Michigan, New Jersey, or New York","29 Years",{"count":50,"type":22},500,"INTERVENTIONAL",[53],"NA","This is a randomized controlled trial to test the effectiveness of an interactive educational app-based digital intervention that provides knowledge and support to transgender and gender-diverse (TGD) young adults ages 18-29 years and their caregivers. The goal of the study is to examine the effects of exposure to the app on TGD young adult mental health outcomes.\n\nParticipants will be randomized to an Immediate Arm (access to a digital platform, plus usual care) or a Deferred Arm (usual care; access to the digital platform at 6 mo). Usual care consists of access to published resources and community support organizations, if available. The list of resources will include contact information for a suicide prevention hotline. For each Arm, the intervention period will last 6 months, followed by 6 months of observation, during which access to the intervention is maintained. Assessments will be performed at baseline, 3, 6, and 12 months to document changes in mental health outcomes, and the two groups will be compared.\n\nThe investigators plan to enroll 500 TGD young adults and their caregivers, with at least 50% (250 participants) to identify as Black, Indigenous, People of Color (BIPOC) and 50% (125 TGD young adults, 125 caregivers) to be young adult-caregiver dyads.\n\nOngoing process reassessments will be performed to maximize effectiveness of the intervention, including focus groups and in-depth interviews with TGD young adults, caregivers, and providers, as well as analysis of data collected through the digital platform and participant surveys. Investigators will account for sociodemographic characteristics such as race and ethnicity, age, gender identity, education status, existing mental health conditions, and history of suicidal ideation or attempt. Data will be analyzed across racial minority groups to ensure that the intervention is effective for all racial minorities; if there are discrepancies in effectiveness, additional mixed methods evaluation will be performed to identify and address potential causes.",[56,57,27],"Transgender Persons","Health Services for Transgender Persons","2025-08-15",{"date":60,"type":32},"2025-08-20",{"date":62,"type":32},"2025-04-23",{"date":64,"type":22},"2026-08-31",{"name":66,"class":39},"Boston Children's Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100589399","the-copenhagen-gender-identity-cohort-100589399","NCT06953908","The Copenhagen Gender Identity Cohort","KIK","Inclusion Criteria:\n\n* All patients referred to The Center for Gender Identity in Copenhagen\n\nExclusion Criteria:\n\n* Inability to read and understand Danish",{"count":75,"type":22},2000,"The goal of this observational study is to systematically collect data on adults seeking medical and surgical treatments for gender incongruence. This prospective, longitudinal cohort aims to generate insights into the safety, effectiveness, and overall satisfaction with current treatments. Additionally, the study seeks to identify areas for improvement and support healthcare professionals in making informed decisions. Most importantly, it aims to enhance the quality of life for transgender and gender-diverse individuals by ensuring that the care they receive aligns with their needs and goals.\n\nParticipants will include patients seeking treatment at the Copenhagen Center for Gender Identity, Denmark. Data collection will be both clinician- and patient-reported. Participants will be asked to complete online surveys at baseline, after the assessment process, and annually if they initiate hormone therapy. The study will systematically gather information on gender identity and transition experiences, sociodemographics, self-medication, health status, self-reported quality of life, and treatment preferences. Additionally, detailed records of treatment courses and specific interventions will be collected from all involved healthcare providers across specialties.\n\nThe study will evaluate the effects of different treatment options, both in the short and long term. It will explore how quality of life is associated with gender identity, transition, sociodemographics, lifestyle, and health, as well as assess the medical impact of various treatments, including counseling, hormone therapy, and surgery. Furthermore, the study will investigate the prevalence of side effects and complications related to treatment, as well as factors influencing treatment discontinuation, including cases of detransition.\n\nFinally, the project will focus on quality indicators such as waiting times and patient satisfaction, contributing to the ongoing development of high-quality, patient-centered care for transgender and gender-diverse individuals.",[27,78,79],"Gender Dysphoria, Adult","Gender Incongruence",[27,79],"2025-04-29",{"date":83,"type":32},"2025-05-01",{"date":85,"type":32},"2022-02-01",{"date":87,"type":22},"2032-01-31",{"name":89,"class":39},"Rigshospitalet, Denmark",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":101,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":40},"100567581","puberty-testosterone-and-brain-development-100567581","NCT06670053","Puberty, Testosterone, and Brain Development","Effect of Testosterone on Brain Imaging and Headache in Transmasculine Adolescents","Inclusion Criteria:\n\n1. transmasculine and gender diverse\n2. assigned female at birth\n3. age 12-20 years at the time of enrollment\n4. plan to start testosterone clinically in \\\u003C 6 months\n5. if taking gonadotropin releasing hormone agonist (GnRHa, puberty blocker), was started on this type of drug 3+ months prior to enrollment\n\nExclusion Criteria:\n\n1. cognitive or psychiatric impairment resulting in inability to tolerate or perform the study procedures\n2. known history of stroke, multiple sclerosis, or other serious neurologic condition\n3. prior diagnosis of Turner Syndrome (monosomy X) or other difference of sexual development\n4. prior diagnosis of polycystic ovarian syndrome (PCOS)\n5. uncontrolled or untreated hypothyroidism\n6. MRI-specific exclusion criteria: (Weight \\> 500 lbs, severe claustrophobia, certain type of metal in body)","12 Years","20 Years",{"count":100,"type":22},100,"2 Years","Transmasculine youth (female sex assigned at birth, male gender identity) who begin clinical gender affirming hormone therapy (GAHT) with testosterone (T) may experience changes in headache. Researchers think this because studies published on effects of giving testosterone to cisgender females (female sex, female gender identity) and transmasculine adults seem to show an effect on pain.\n\nThis research will help us learn more about changes in headache and in brain structure and function in transmasculine youth during the first two years of T. Youth who will be starting T within 6 months, either on puberty blocker or not, as part of their regular medical care can participate and will be asked to attend 4 visits:\n\n* before starting T\n* after 6 months on T\n* after 1 year on T\n* after 2 years on T\n\nAt the visits, they will be asked to:\n\n* answer questions and surveys about their health\n* have a brain MRI done\n* give a small sample of blood\n\nand at their first visit, complete a physical exam. Some participants can also do a brief test of pain sensitivity. All participants will be asked to complete a headache diary for the first 6 months, for 1 month after the 1 year visit, and for 1 month after the 2 year visit.",[27,104,105,106],"Gender Dysphoria in Adolescents and Adults","Headache","Transgender",[108,109,110,111,112,113,114],"resting-state functional connectivity","pain task","fMRI","MRI","migraine","gender affirming hormone therapy","testosterone","2025-04-02",{"date":117,"type":32},"2025-04-03",{"date":119,"type":32},"2024-12-31",{"date":121,"type":22},"2026-12",{"name":123,"class":39},"University of Colorado, Denver",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":132,"minAge":18,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":51,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":145,"leadSponsor":147,"locationsCount":40},"100489168","early-mental-response---the-emre-study-100489168","NCT05649605","Early Mental Response - The EMRE Study","Early Mental Response to Hormonal Treatment in Transgender Men - The EMRE Study","EMRE","Inclusion criteria:\n\n1. Well-informed written consent to participate in the study.\n2. Transgender man given the ICD-10 diagnosis of transsexualism.\n3. A desire for complete gender-confirming hormonal treatment.\n4. Approved for Nebido treatment by a clinically responsible Endocrinologist.\n\nExclusion criteria:\n\n1. A concomitant hormonal condition affecting the gonadal axis (e.g. Congenital Adrenal Hyperplasia, Poly Cystic Ovary Syndrome, Complete Androgen Insensitivity Syndrome, Partial Androgen Insensitivity Syndrome, untreated thyroid disease, untreated hypercortisolism, etc.).\n2. A disability that prevents the patient from fully participating in the study.\n3. Treatment with steroid hormones (androgens, estrogens, progestogens, or continuous treatment with oral corticosteroids within the last three months).\n4. Previous use of hormone preparations without a doctor's prescription.\n5. Laboratory samples significantly outside the normal reference range.\n6. Anamnestic or investigational suspicion of breast cancer or existing or previous liver tumors.\n7. Levels of P-ASAT, P-ALAT, or P-GT at the screening time that are\\> 2 times the reference range.\n8. Hypersensitivity to the active substance or to any of the excipients.\n9. Ongoing pregnancy or wishes for a pregnancy in the near future.","FEMALE","99 Years",{"count":135,"type":22},70,[53],"Primary question: Does transgender men's experience of gender incongruence improve within 6 weeks of hormonal treatment compared to placebo? Long before any bodily changes occur.\n\nSecondary question: Does transgender men´s experience of self-esteem, quality of life, sexual desire, aggression, depression\u002Fanxiety, impulsiveness, and emotional reactivity improve during 6 weeks of cross-sex hormone therapy compared to placebo? Gender dysphoria is a condition characterized by a perceived incongruence between the body and identity. For several decades this condition has been treated with cross-sex hormone therapy and surgery, among others, in order to change the body to be more congruent with the perceived gender identity. Patient satisfaction with this treatment is very high where an overwhelming majority of patients live the rest of their lives according to their perceived gender. A clinical observation, however, is that most patients experience that the congruence between the perceived gender and the assigned one improves very quickly on hormonal treatment. Long before any changes to the body have taken place. This may be partly due to relief from having finally started treatment (i.e. a psychological\u002Fsocial explanation) but an alternative (and much more likely) explanation is that the hormonal treatment directly affects the brain. Since the cause of gender dysphoria is unknown today, this study is therefore a step in trying to clarify the mechanism. In addition, it is of value to be able to demonstrate the benefits of hormonal treatment in these patients. Finally, there is a basic research motive for this study. The effect of sex hormones on the brain is very well known from a clinical perspective but all the more unknown from a research perspective. This study will contribute knowledge in this area.",[139,27,140],"Gender Dysphoria","Gender Issues","2023-03-07",{"date":143,"type":32},"2023-03-08",{"date":141,"type":32},{"date":146,"type":22},"2026-12-30",{"name":148,"class":39},"Karolinska University Hospital"]